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Background: In recent years, drug coated balloons have emerged as treatment option for
PCI. The present registry aims to evaluate the safety and efficacy of the Pantera Lux
Paclitaxel Coated Balloon in a real world setting.
Methods: Between April 2010 and April 2011, 363 diabetic patients were enrolled at 50
sites in 12 countries. Clinical follow-up was performed at 1, 6 and 12 months. The
primary endpoint was MACE, a composite of all death, non-fatal MI and clinically driven
TVR, at 6 months. Secondary endpoints include MACE at 1 and 12 months. All reported
MACE were adjudicated by an independent clinical events committee.
Results: Two hundred fifty-nine men (71.3%) and 104 female (28.7%) with a mean age
of 67.4 10.2 yrs have been enrolled. One hundred forty-two patients (39.4%) were
insulin dependent. Eighty-six patients (23.7%) presented with congestive heart failure and
195 patients (53.7%) had a history of previous MI. The majority of patients presented with
stable angina (n184, 50.7%) followed by unstable angina (n107, 29.5%). A total of
388 lesions were treated, mainly located in LAD (n144, 37.1%) and RCA (n136,
35.1%). The mean reference vessel diameter was 2.9 mm and the mean target lesion
length was 15.6 mm. Three hundred forty lesions (87.6%) were in-stent restenotic (ISR)
lesions. Thereof 165 lesions were in a BMS (48.5%) and 172 lesions in a DES (50.6%).
The majority of ISR lesions were diffuse (n159, 48.3%, Mehran class II) or focal
(n104, 31.6%, Mehran class I). Follow-up compliance at 6 month follow up is 93.9%.
The MACE rate (hierarchical) at 6 months is 11.2% including 11 all death (3.2%, 6
cardiac death [1.8%]), 7 non-fatal MI (2.1%) and 20 clinically driven TVR (5.9%). In 15
cases (4.4%) a target lesion revascularization was needed. Twelve months MACE data
will be presented.
Conclusions: Treatment with the Pantera Lux Paclitaxel Coating Balloon showed
excellent acute and mid term performance in diabetic patients with mainly ISR lesions.
Efficacy and safety are demonstrated by low revascularization rates and low non-fatal MI
rate.
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Background: Drug coated balloons using Paclitaxel have demonstrated to be clinically
effective in selected clinical settings. In contrast, Sirolimus is not easily transferred to the
vessel wall using current coating Methods and tissue levels cannot be maintained long
enough to control restenosis. In this study, we aimed to evaluate the feasibility of delivery
and long term retention of Sirolimus nanoparticles delivered through a novel porous
angioplasty balloon in normal porcine coronary arteries.
Methods: A total of 155 coronary arterial segments were treated with a porous
angioplasty balloon delivering Sirolimus nanoparticles (Caliber Therapeutics, New Hope,
PA) at a 20% overstretch ratio. Coronary angiography was performed at baseline and after
delivery to assess safety. Treated coronary segments were harvested immediately after
Sirolimus delivery (n25) and at 4 (n30), 7 (n84), 21 (n7) and 28 days (n9) and
analyzed to detect tissue Sirolimus levels. Distal tissue samples (distal myocardium, lung,
liver and kidney) were also collected to determine Sirolimus systemic distribution
following local drug delivery.
Results: The Sirolimus levels found immediately after balloon delivery were 422.6110
ng/mg. Subsequently, Sirolimus tissue levels progressively decreased at 4 (200.1380.4
ng/mg) and 7 (49.817.1 ng/mg) and 21 (32.713.6 ng/mg) days. At last follow up (28
days), Sirolimus tissue levels were still above the target therapeutic levels (18.5  9.6
ng/mg). At any given time point, Sirolimus concentrations were 300-fold higher in
coronary segments than in distal tissue samples. Drug levels in remote tissues were
undetectable after 7 days.
Conclusions: The local arterial delivery of Sirolimus nanoparticles using a novel porous
balloon delivery system was safe and capable of achieving long term intra-arterial drug
levels without significant systemic residual exposure in a porcine model.
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Background: The mechanism of action of Drug Coated Balloons (DCB) is not fully
understood. It’s suggested that following balloon dilatation, Paclitaxel is deposited on the
vascular luminal surface and serves as a natural drug delivery system. We hypothesize that
fibrin acts as a biological glue covering Paclitaxel deposits following balloon delivery. In
this study, we aimed to evaluate the effect of the number of balloon inflations on luminal
fibrin deposits over time.
Methods: A total of 22 porcine femoral arterial segments were randomized to 1x (n4),
2x (n7) and 6x (n11) PCB inflations (Cotavance, Medrad, Inc. Indianola, PA) and
followed for 7 days. Additional 7 arterial segments received 6x PCB inflations and were
followed for 14 (n2) and 30 days (n5). Vessels were harvested for the evaluation of
luminal fibrin deposition using a semi-quantitative score.
Results: A total of 148 vessels segments were analyzed in the 7 day study (1x, n35; 2x,
n37; 6x, n76) and 40 slides in the long term study (14 days, n11; 30 days, n29).
Fibrin deposits when present, were found to be deposited on the luminal surface of the
vessel and covering crystalline material. At 7 days following PCB inflation, fibrin scores
significantly increased according to the number of inflations. Single PCB inflation showed
the lowest fibrin score (0.20.5) followed by double PCB inflation (0.430.55). Six
inflations showed a significantly increase in fibrin score (1.880.71, p 0.001). In the
analysis of PCB over time, a peak in fibrin deposition was seen at 14 days (2.451.04)
before it decreases at 30 days (1.660.90).
Conclusions: Our study suggests that fibrin gets deposited on the surface of the vessel in
a dose dependent fashion following PCB delivery and may play a major role in the
creation of drug reservoirs and long term intra-vessel drug delivery. The course of the
luminal fibrin deposition overtime suggests that this process peaks at 14 days and starts
to resorb thereafter.
TCT-599
Angiographic and clinical outcome in the treatment of Restenosis of Drug
Eluting Stents with drug coated balloons in diabetics: Insights from the
PEPCAD-DES study
Harald Rittger1, Johannes Brachmann2, Matthias Waliszewski3, Ralf Birkemeyer4,
Christoph Garlichs1, Jochen Wöhrle5
1Universitätsklinikum Erlangen, Medizinische Klinik 2, Erlangen, Germany,
2Klinikum Coburg, Medizinische Klinik 2, Coburg, Germany, 3B. Braun Vascular
Systems, Melsungen, Germany, 4Klinik für Kardiologie, Universitätsklinikum
Rostock, Rostock, Germany, 5Dept. of Cardiology, University of Ulm, Ulm,
Germany, Ulm, Germany
Background: The PEPCAD-DES Study showed a significantly lower late loss with the
use of a drug coated balloon in comparison (SeQuent Please balloon catheter (B.Braun
Melsungen AG, Germany) in comparison to balloon angioplasty alone in the treatment of
instent-restenosis of drug-eluting stents (DES). In the presence of diabetes there are higher
rates of ISR reported in comparison to a healthy population. Purpose of this study was to
investigate the impact of diabetes mellitus on late lumen loss and angiographic restenosis
in patients, who were treated with a drug-cotaed balloon (DCB) in comparison to balloon
angioplasty alone (POBA) for instent-restenosis (ISR) of drug-eluting stents (DES).
Methods: 110 patients with an ISR of either Cypher-, Taxus- or XienceV-stent in a native
coronary artery with indication for percutaneous coronary intervention were included in
six centers in Germany. Exclusion criteria were: acute myocardial infarction, chronic total
occlusion, lesion in grafts, bifurcation lesion, left main lesion, restenosis and in-stent
restenosis, contraindication for acetylsalicylic acid or clopidogrel. All patients were
scheduled for control angiography at 6 months.
Results: 38 patients were randomized to POBA and 72 patients to DCB. Of these 26
(36.1%) pts. of the DCB-group and 13 (34.2%) were diabetics. DCB as compared with
POBA significantly reduced late loss in diabetics and non-diabetics, respectively. At
angiographic 6 month follow-up late lumen loss (LLL) in patients treated with a DCB
(n22) was 0.510.72 mm in diabetics, and 0.390.54 mm in non-diabetics (n42).In
patients treated with POBA LLL was 1.450.85 mm in the diabetic subgroup and
0.910.71 mm in non-diabetics (n24). Rates of target lesion revascularization(TLR)
rates were significantly lower with DCB versus POBA for non-diabetics (15.2% vs.
36.0%; p0.045), but not for diabetics (15.4% vs. 38.5%; p0.107) Overall rates of
major adverse cardiac events (MACE) were signific.
Conclusions: Paclitaxel coated balloon angioplasty was superior to POBA for treatment
of DES-ISR and reduced significantly MACE-rates in diabetics and non-diabetics. DCB
effect on late loss was more effective in patients without diabetes.
TUESDAY, OCTOBER 23, 8:00 AM–10:00 AMwww.jacc.tctabstracts2012.com
JACC Vol 60/17/Suppl B | October 22–26, 2012 | TCT Abstracts/POSTER/Drug-Coated Balloon B173
P
O
ST
E
R
S
